U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C29H29FN4O
Molecular Weight 468.5652
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DERAZANTINIB

SMILES

COCCNCCC1=CC(NC2=NC=C3C[C@@H](C4=CC=CC=C4F)C5=CC=CC=C5C3=N2)=CC=C1

InChI

InChIKey=KPJDVVCDVBFRMU-AREMUKBSSA-N
InChI=1S/C29H29FN4O/c1-35-16-15-31-14-13-20-7-6-8-22(17-20)33-29-32-19-21-18-26(24-10-4-5-12-27(24)30)23-9-2-3-11-25(23)28(21)34-29/h2-12,17,19,26,31H,13-16,18H2,1H3,(H,32,33,34)/t26-/m1/s1

HIDE SMILES / InChI

Molecular Formula C29H29FN4O
Molecular Weight 468.5652
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Derazantinib (ARQ 087) is an investigational, oral, multi-kinase inhibitor designed to preferentially inhibit the FGFR family of kinases with demonstrated activity in FGFR2 genetic alterations, including fusions. In human cancers, FGFRs have been found to be dysregulated by multiple mechanisms, including aberrant expression, mutations, chromosomal rearrangements, and amplifications. FGFR dysregulation has been identified as a driver in a number of cancers, including iCCA, cholangiocarcinoma, bladder, endometrial, breast, gastric, lung and ovarian. Current scientific literature suggests FGFR alterations exist in anywhere from 5% to 40% of these cancers. Derazantinib is a potent FGFR inhibitor that shows strong anti-proliferative activity in cell lines harboring FGFR2 alterations. In clinical testing, the molecule has demonstrated activity in cancerous tumors harboring FGFR2 fusions in iCCA and bladder cancers.

Originator

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PubMed

PubMed

TitleDatePubMed
Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation.
2016
Patents

Patents

Sample Use Guides

In Vivo Use Guide
ARQ-087 orally at dose levels specified for their respective dose cohorts on a 28-day schedule. Dosing will begin at 25 mg every other day (QOD) and will escalate until the maximum tolerated dose (MTD)
Route of Administration: Oral
In Vitro Use Guide
NCI-H716 and SNU-16 cells were plated and incubated at 37°C overnight and subsequently treated with 0.1 μM or 1 μM of ARQ 087 for 24 or 72 hours. The cells were fixed and stained with Cycletest Plus Reagent kit (BD Biosciences, Franklin Lakes, NJ) according to the manufacturer’s instructions, and cell cycle profiles were analyzed using a FACS Calibur flow cytometer
Substance Class Chemical
Created
by admin
on Mon Oct 21 22:41:41 UTC 2019
Edited
by admin
on Mon Oct 21 22:41:41 UTC 2019
Record UNII
N9B0H171MJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DERAZANTINIB
INN  
USAN   INN  
Official Name English
ARQ 087
Code English
DERAZANTINIB [USAN]
Common Name English
ARQ087
Code English
DERAZANTINIB [INN]
Common Name English
BENZO(H)QUINAZOLIN-2-AMINE, 6-(2-FLUOROPHENYL)-5,6-DIHYDRO-N-(3-(2-((2-METHOXYETHYL)AMINO)ETHYL)PHENYL)-, (6R)-
Systematic Name English
ARQ-087
Common Name English
DERAZANTINIB [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1967
Created by admin on Mon Oct 21 22:41:41 UTC 2019 , Edited by admin on Mon Oct 21 22:41:41 UTC 2019
NCI_THESAURUS C129825
Created by admin on Mon Oct 21 22:41:41 UTC 2019 , Edited by admin on Mon Oct 21 22:41:41 UTC 2019
Code System Code Type Description
ChEMBL
CHEMBL3545421
Created by admin on Mon Oct 21 22:41:41 UTC 2019 , Edited by admin on Mon Oct 21 22:41:41 UTC 2019
PRIMARY
CAS
1814961-15-3
Created by admin on Mon Oct 21 22:41:41 UTC 2019 , Edited by admin on Mon Oct 21 22:41:41 UTC 2019
NO STRUCTURE GIVEN
NCI_THESAURUS
C104267
Created by admin on Mon Oct 21 22:41:41 UTC 2019 , Edited by admin on Mon Oct 21 22:41:41 UTC 2019
PRIMARY
INN
10488
Created by admin on Mon Oct 21 22:41:41 UTC 2019 , Edited by admin on Mon Oct 21 22:41:41 UTC 2019
PRIMARY
PUBCHEM
46834118
Created by admin on Mon Oct 21 22:41:41 UTC 2019 , Edited by admin on Mon Oct 21 22:41:41 UTC 2019
PRIMARY
CAS
1234356-69-4
Created by admin on Mon Oct 21 22:41:41 UTC 2019 , Edited by admin on Mon Oct 21 22:41:41 UTC 2019
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY